|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil显示文摘BACKGROUND Inflammatory bowel diseases(IBD)have been associated with a low quality of life(QoL)and a negative impact on work productivity compared to the general population.Information about disease control,patient-reported outcomes(PROs),treatment patterns and use of healthcare resources is relevant to optimizing IBD management.AIM To describe QoL and work productivity and activity impairment(WPAI),treatment patterns and use of healthcare resources among IBD patients in Brazil.METHODS A multicenter cross-sectional study included adult outpatients who were previously diagnosed with moderate to severe Crohn’s disease(CD)or ulcerative colitis(UC).At enrolment,active CD and UC were defined as having a Harvey Bradshaw Index≥8 or a CD Activity Index≥220 or calprotectin>200μg/g or previous colonoscopy results suggestive of inadequate control(per investigator criteria)and a 9-point partial Mayo score≥5,respectively.The PRO assessment included the QoL questionnaires SF-36 and EQ-5D-5L,the Inflammatory Bowel Disease Questionnaire(IBDQ),and the WPAI questionnaire.Information about healthcare resources and treatment during the previous 3 years was collected from medical records.Chi-square,Fisher’s exact and Student’s t-/Mann-Whitney U tests were used to compare PROs,treatment patterns and the use of healthcare resources by disease activity(α=0.05).RESULTS Of the 407 patients in this study(CD/UC:64.9%/35.1%,mean age 42.9/45.9 years,54.2%/56.6%female,38.3%/37.1%employed),44.7%/25.2%presented moderate-to-severe CD/UC activity,respectively,at baseline.Expressed in median values for CD/UC,respectively,the SF-36 physical component was 46.6/44.7 and the mental component was 45.2/44.2,the EQ-visual analog scale score was 80.0/70.0,and the IBDQ overall score was 164.0/165.0.Moderate to severe activity,female gender,being unemployed,a lower educational level and lower income were associated with lower QoL(P<0.05).Median work productivity impairment was 20%and 5%for CD and UC patients,respectively,and activity impairment was 30%,the latter being higher among patients with moderate to severe disease activity compared to patients with mild or no disease activity(75.0%vs 10.0%,P<0.001).For CD/UC patients,respectively,25.4%/2.8%had at least one surgery,38.3%/19.6%were hospitalized,and 70.7%/77.6%changed IBD treatment at least once during the last 3 years.The most common treatments at baseline were biologics(75.3%)and immunosuppressants(70.9%)for CD patients and 5-ASA compounds(77.5%)for UC patients.CONCLUSION Moderate to severe IBD activity,especially among CD patients,is associated with a substantial impact on QoL,work productivity impairment and an increased number of IBD surgeries and hospitalizations in Brazil. | Rogerio Serafim Parra Julio MF Chebli Heda MBS Amarante Cristina Flores Jose ML Parente Odery Ramos Milene Fernandes Jose JR Rocha Marley R Feitosa Omar Feres Antonio S Scotton Rodrigo B Nones Murilo M Lima Cyrla Zaltman Carolina D Goncalves Isabella M Guimaraes Genoile O Santana Ligia Y Sassaki Rogerio S Hossne Mauro Bafutto Roberto LK Junior Mikaell AG Faria Sender J Miszputen Tarcia NF Gomes Wilson R Catapani Anderson A Faria Stella CS Souza Rosana F Caratin Juliana T Senra Maria LA Ferrari | 2019 | World Journal of Gastroenterology2019，25，38： | 2 |
| 2 | Comparison between sirolimus-eluting stents and intracoronary catheter-based beta radiation for the treatment of in-stent restenosis 显示文摘 | Feres F Munoz J S Abizaid A | 2005 | Am J Cardiol2005，96，12： | 1 |
| 3 | Three vs twelvemonths of dual antiplatelet therapy after zotarolimus -elutingstents the OPTIMIZE randomized trial 显示文摘 | FERES F COSTA R A ABI2AID A | 2013 | JAMA2013，310，23： | 1 |
| 4 | Departure Processes of BMAP/G/1 Queues 显示文摘 | FERING H W CHANG J F | 2001 | Queueing Systems2001，39，： | 1 |
| 5 | Use of rapamycin-impregnated stents in coronary arteries显示文摘 | Sousa JE Sousa AG Costa MA Abizaid AC Feres F | 2003 | Transplant Proc2003，35，3： | 1 |
| 6 | Comparison between sirolimuseluting stents and intracoronary catheter-based beta radiation for the treatment of in-stent restenosis显示文摘 | Feres F Munoz JS Abizaid A | 2005 | Am J Cardiol2005，96，： | 1 |
| 7 | Gene selection based on multi-class support vector machines and genetic algorithms 显示文摘 | Bruno Feres de Souza Andre Ponce de Leon F de Carvalho | 2005 | Genetics and Molecular Research2005，4，3： | 1 |
| 8 | Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OP- TIMIZE randomized trial显示文摘 | Feres F Costa RA Abizaid A | 2013 | JAMA2013，310，23： | 1 |
| 9 | Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents:the OPTIMIZE randomized trial显示文摘 | FERES F COSTA R A ABIZAID A | 2013 | JAMA2013，310，23： | 1 |
| 10 | Sulfa- tion in lead-acid batteries 显示文摘 | Catherino H A Feres F F Trinidad F | 2004 | Journal oj' Power Sources2004，129，1： | 1 |
| 11 | Lateral X- ray view of the skull for the diagnosis of adenoid hyper- trophy:a systematic review显示文摘 | Feres M F Hermann J S Cappellette M Jr | 2011 | Int J Pediatr Otorhinolaryn- gol2011，75，： | 1 |
| 12 | Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents:the OPTIMIZE randomized trial显示文摘 | Feres F Costa RA Abizaid A | 2013 | JAMA2013，310，23： | 1 |
| 13 | Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial 显示文摘 | Feres F Costa RA Abizaid A | 2013 | JAMA2013，310，23： | 1 |
| 14 | Sulfation in lead acid batteries显示文摘 | Catherino H A Feres F F Trinidad F | 2004 | Journal of Power Sources2004，129，1： | 1 |
| 15 | Drug-eluting stents vs bare metal stents for the treatment of large coronary vessels 显示文摘 | Quizhpe AR Feres F de Ribamar Costa J Jr | 2007 | Am Heart J2007，152，2： | 1 |
| 16 | Low and very low birth weight in infants conceived with use of assisted Reproductive technology显示文摘 | Chievel A Meiklesf F Feree C | | 0，，10： | 1 |
| 17 | Very late thrombosis after drug-eluting stems显示文摘 | Costa JR Jr Abizaid A | 2006 | Catheter Cardiovasc Interv2006，68，1： | 1 |
| 18 | Vessel remodelingand plaque distribution in side branch of complex coronarybifurcation lesions : a grayscale intravascular ultrasound study显示文摘 | COSTA R A FERES F STAICO R | 2013 | Int J Cardiovasc Imaging2013，29，8： | 1 |
| 19 | Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil显示文摘BACKGROUND Crohn’s disease(CD)and ulcerative colitis(UC)are inflammatory bowel diseases(IBDs)with a remission-relapsing presentation and symptomatic exacerbations that have detrimental impacts on patient quality of life and are associated with a high cost burden,especially in patients with moderate-to-severe disease.The Real-world Data of Moderate-to-Severe Inflammatory Bowel Disease in Brazil(RISE BR)study was a noninterventional study designed to evaluate disease control,treatment patterns,disease burden and health-related quality of life in patients with moderate-to-severe active IBD.We report findings from the prospective follow-up phase of the RISE BR study in patients with active UC or CD.AIM To describe the 12-mo disease evolution and treatment patterns among patients with active moderate-to-severe IBD in Brazil.METHODS This was a prospective,noninterventional study of adult patients with active Crohn’s disease(CD:Harvey-Bradshaw Index≥8,CD Activity Index≥220),inadequate CD control(i.e.,calprotectin>200μg/g or colonoscopy previous results),or active ulcerative colitis(UC:Partial Mayo score≥5).Enrollment occurred in 14 centers from October 2016 to February 2017.The proportion of active IBD patients after 9-12 mo of follow-up,Kaplan-Meier estimates of the time to mild or no activity and a summary of treatment initiation,discontinuation and dose changes were examined.RESULTS The study included 118 CD and 36 UC patients,with mean±SD ages of 43.3±12.6 and 44.9±16.5 years,respectively.The most frequent drug classes at index were biologics for CD(62.7%)and 5-aminosalicylate derivates for UC patients(91.7%).During follow-up,65.3%of CD and 86.1%of UC patients initiated a new treatment at least once.Discontinuations/dose changes occurred in 68.1%of CD patients[median 2.0(IQR:2-5)]and 94.3%of UC patients[median 4.0(IQR:3-7)].On average,CD and UC patients had 4.4±2.6 and 5.0±3.3 outpatient visits,respectively.The median time to first mild or no activity was 319(IQR:239-358)d for CD and 320(IQR:288-358)d for UC patients.At 9-12 mo,22.0%of CD and 20.0%of UC patients had active disease.CONCLUSION Although a marked proportion of active IBD patients achieved disease control within one year,the considerable time to achieve this outcome represents an unmet medical need of the current standard of care in a Brazilian real-world setting. | Ligia Yukie Sassaki Sender J Miszputen Roberto Luiz Kaiser Junior Wilson R Catapani Mauro Bafutto António S Scotton Cyrla Zaltman Julio Pinheiro Baima Hagata S Ramos Mikaell Alexandre Gouvea Faria Carolina D Gonçalves Isabella Miranda Guimaraes Cristina Flores Heda M B S Amarante Rodrigo Bremer Nones JoséMiguel Luz Parente Murilo Moura Lima Júlio Maria Chebli Maria de Lourdes Abreu Ferrari Julia F Campos Maria G P Sanna Odery Ramos Rogério Serafim Parra Jose J R da Rocha Omar Feres Marley R Feitosa Rosana Fusaro Caratin Juliana Tosta Senra Genoile Oliveira Santana | 2021 | World Journal of Gastroenterology2021，27，23： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员